title: Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases.
abstract: A multicenter, randomized Phase 2 study that compared patients, affected by colorectal liver metastases, who received intrahepatic arterial infusion with two different schedules of cisplatin, bolus vs. continuous infusion, and systemic 5-fluorouracil.
  
  
  OBJECTIVE
  The aim of this study was to validate results of a previous Phase 2 trial on bolus cisplatin intrahepatic arterial infusion, which reported a 47 percent response rate and a 32 percent 4-year survival rate for Gennari's Stage 2 patients, with a high rate of neurologic, gastrointestinal, and hematologic toxicity.
  
  
  METHODS
  One hundred nine patients were randomized in a Phase 2 study to receive cisplatin intrahepatic arterial infusion (24 mg/m2/day, 1-->5, bolus vs. continuous infusion) and systemic intravenous 5-fluorouracil (250, 375, or 500 mg/m2/day, 1-->5; escalating doses, respectively, at cycles I, II, III, and VI). To avoid neurotoxicity a maximum of six cycles was administered.
  
  
  RESULTS
  Preliminary results for the 78 evaluable patients are similar to those of the previous study: response rate 46 percent and at a median follow-up of 16.5 months, the overall survival was 16.5 months, with 45 percent of the patients who received more than 3 cycles alive at 3 years. Toxicity, evaluable in 99 patients, showed a decreased incidence of neurotoxicity and a tolerable gastrointestinal and hematologic toxicity, lower in the cisplatin continuous infusion arm.
  
  
  CONCLUSIONS
  This study clearly shows that cisplatin intrahepatic arterial infusion is able to provide a good palliative effect with a tolerable toxicity.
authors.affiliation: University of Rome, La Sapienza, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Cortesi
authors.forename: L
authors.initials: L
authors.lastname: Capussotti
authors.forename: P
authors.initials: P
authors.lastname: Di Tora
authors.forename: E
authors.initials: E
authors.lastname: Mannella
authors.forename: V
authors.initials: V
authors.lastname: Casaldi
authors.forename: D
authors.initials: D
authors.lastname: Civalleri
authors.forename: G B
authors.initials: GB
authors.lastname: Morandi
authors.forename: P P
authors.initials: PP
authors.lastname: Da Pian
authors.forename: A
authors.initials: A
authors.lastname: Padovani
authors.forename: A
authors.initials: A
authors.lastname: Callopoli
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D002945:Cisplatin; D005472:Fluorouracil